Section 232 probe reignites tariff uncertainty for medtech firms

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtech companies face more tariff uncertainty as the Trump administration opens a Section 232 investigation into medical equipment. The Department of Commerce disclosed the probe late Wednesday, although it had started several weeks earlier, on Sept. 2. Medical device firms are still looking into the potential implications. Industry group Advamed, which has been lob ...